Clinical Trial Update: HL-085+Vemurafenib to Treat Advanced Melanoma Patients With BRAF V600E/K Mutation [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating HL-085 in combination with vemurafenib for advanced melanoma with BRAF V600E/K mutation.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Melanoma

Drugs mentioned

• HL-085
• Vemurafenib (vemurafenib)

Snippet

Sponsor: Shanghai Kechow Pharma, Inc. | Conditions: Melanoma | Phase 2 | Status: UNKNOWN